1. Scrip

Obituary: Indian Generics Industry Torchbearer Dilip Shah

 
• By Anju Ghangurde

Indian industry veteran and secretary general of the Indian Pharmaceutical Alliance, Dilip Shah, has died aged 77. Shah, a former commercial director of Pfizer in India, played a pivotal role in ensuring that the Indian generic industry's voice was heard.

India
India Remembers Key Industry Figure Dilip Shah • Source: Shutterstock

When Dilip Shah, secretary general of the Indian Pharmaceutical Alliance (IPA), which represents leading domestic firms, sought early retirement at Pfizer India way back in 1997, he told this reporter that he wished to "play a bigger role in the drug industry with greater freedom." Undoubtedly he did, and with great panache over the next two decades. Worse still for Pfizer, he did so from the "other side", largely representing and emerging as the face of the Indian generic industry. And few can deny that the silver-haired Shah, whose stint with Pfizer lasted around 30 years, could single-handed take on generic industry naysayers.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from India

More from Focus On Asia

NIH Funding Cut Left Less Money On R&D Table, Tariffs Would Add To Woes: Aragen’s CEO

 
• By Vibha Ravi

Funding cuts at the National Institutes of Health, big pharma’s US onshoring moves, GCC partnerships and talks with the Indian government to solve intellectual property challenges are discussed in an interview with Aragen’s CEO, who is also keenly watching the Trump administration’s moves on pharma tariffs

Akeso Explains Ivonescimab Prelim OS Data After Investors’ Negative Reactions

 
• By Dexter Jie Yan

Akeso explains the circumstances behind the release of preliminary overall survival data from a head-to-head Phase III trial with ivonescimab in lung cancer, which some investors viewed as disappointing.

Novotech CEO On Flexible Trial Solutions Amid Tariff, Geopolitical Tensions

 
• By Anju Ghangurde

Novotech's CEO talks about rising interest for trials in regions with “regulatory agility” and “strategic insulation” from geopolitical complexity, especially among emerging and mid-sized biotech sponsors. Operational "reassessment” among some sponsors on exposure to China-based CROs/CRDMOs is another area he discussed.